Module

New Data on Hepatitis B Virus Treatment

Source: Hepatitis Annual Update 2005

New Data on Hepatitis B Virus Treatment

CME Program Director: Patrick J. Lynch, MD

Faculty:

Hui Chee-Kin, MD
George K. K. Lau, MD

CME CREDIT INFORMATION

Release Date: 10/26/05

Expiration Date: 10/25/06

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss preclinical anti-HBV agents.
Describe drugs with anti-hepatitis B virus (HBV) activity already approved by the FDA for treatment of HBV or other indications.
Review anti-HBV drugs that are currently in clinical trials.

Content includes:

Interferon
Lamivudine
Adefovir Dipivoxil
Peginterferon Alfa
Entecavir
Agents Under Development: Telbivudine
Tenofovir
Clevudine
Emtricitabine
Pradefovir
LY582563 (MCC-478)
LB80380
2',3'-dideoxy-3'-fluoroguanosine (FLG)
Gene Therapy: Small Interfering RNA
Viral Packaging Inhibitors
Combination Therapy

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.